(7α,17β)-7-ethenyl-17-hydroxyestr-4-en-3-one | 293303-47-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (7α,17β)-7-ethenyl-17-hydroxyestr-4-en-3-one
• 英文别名: (7alpha,17beta)-7-Ethenyl-17-hydroxyestr-4-en-3-one；(7S,8R,9S,10R,13S,14S,17S)-7-ethenyl-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 293303-47-6
• 化学式: C₂₀H₂₈O₂
• 分子量: 300.441
• InChiKey: DNPJGOCSGIFUFU-TYXSOELRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (7α,17β)-7-ethenyl-17-hydroxyestr-4-en-3-one 在 盐酸羟胺 作用下， 以 吡啶 为溶剂， 生成 (3Z,7α,17β)-7-ethenyl-3-(hydroxyimino)estr-4-en-17-ol
  参考文献：
  名称：

  ORALLY ACTIVE 7-ALPHA-ALKYL ANDROGENS

  摘要：

  公开号：

  EP1212345B1

文献信息

• Orally active 7.alpha.-alkyl androgens
  申请人：——

  公开号：US20040209853A1

  公开（公告）日：2004-10-21

  Orally Active androgens are derivative of 7&agr;-methyl-19-nortestosterone. The compounds satisfy formula (I) wherein R 1 is O, (H,H), (H,OR), NOR, with R being hydrogen, (C 1-6 ) alkyl, or (C 1-6 ) acyl; R 2 is ethyl optionally substituted by halogen; R 3 is hydrogen, (C 1-2 ) alkyl, or ethenyl; R 4 is (C 1-2 ) alkyl; R 5 is hydrogen, or (C 1-15 )acyl; and the dotted lines indicate optional bonds. 1

  口服活性雄激素是7α-甲基-19-去甲睾酮的衍生物。化合物满足公式（I），其中R1为O，（H，H），（H，OR），NOR，其中R为氢，（C1-6）烷基或（C1-6）酰基; R2为乙基，可选地被卤素取代; R3为氢，（C1-2）烷基或乙烯基; R4为（C1-2）烷基; R5为氢或（C1-15）酰基; 而虚线表示可选的键。
• Orally active androgens
  申请人：——

  公开号：US20020022609A1

  公开（公告）日：2002-02-21

  Novel, orally active androgens are 7&agr;-substituted &Dgr; 14 -nandrolone derivatives. The compounds satisfy the general formula: 1 wherein R 1 is O, (H,H), (H,OR), NOR, with R being hydrogen, (C 1-6 ) alkyl, or (C 1-6 ) acyl; R 2 is selected from the group consisting of (C 2-4 ) alkyl, (C 2-4 ) alkenyl, or (C 2-4 ) alkynyl, each optionally substituted by halogen; or R 2 is cyclopropyl, or cyclopropenyl, each optionally substituted by (C 1-2 ) alkyl, or halogen; R 3 is hydrogen, (C 1-2 ) alkyl, or ethenyl; R 4 is (C 1-2 ) alkyl; R 5 is hydrogen, or (C 1-15 ) acyl; and the dotted lines indicate optional bonds.

  小说，口服活性雄激素是7α-取代Δ14-那种酮衍生物。这些化合物满足通用式：1其中R1为O，（H，H），（H，OR），NOR，其中R为氢，（C1-6）烷基或（C1-6）酰基; R2选自由（C2-4）烷基，（C2-4）烯基或（C2-4）炔基组成的群体，每个都可以选择地被卤素取代; 或R2是环丙基或环丙烯基，每个都可以选择地被（C1-2）烷基或卤素取代; R3为氢，（C1-2）烷基或乙烯基; R4为（C1-2）烷基; R5为氢或（C1-15）酰基; 而虚线表示可选键。
• Novel androgens
  申请人：——

  公开号：US20030100543A1

  公开（公告）日：2003-05-29

  The disclosed invention relates to the unexpected finding of novel steroids which are characterized by a 14&bgr;,15&bgr;-cyclopropane ring and a 17&agr; hydroxymethyl group. These steroids according to the invention are found to have in common an androgenic activity. They can be used for the preparation of an agent for male contraception, as well as for the preparation of a medicament for the treatment of androgen insufficiency.

  本公开发明涉及一种意外发现的新型类固醇，其特征为具有14&bgr;，15&bgr;-环丙烷环和17&agr;羟甲基基团。根据本发明，这些类固醇具有共同的雄激素活性。它们可用于制备男性避孕剂，以及用于制备治疗雄激素不足的药物。
• 14 Beta, 16, 17-methylene steroids as novel androgens
  申请人：——

  公开号：US20040030165A1

  公开（公告）日：2004-02-12

  Disclosed are androgenic steroids of the (14&bgr;,17&agr;)-17-(hydroxymethyl) type. The invention relates to an improvement hereof, which is based on the presence of a &x3B2;-oriented, annellated cyclopropyl group which includes carbon atoms 16 and 17 of the steroid skeleton, i.e. a 16,17&bgr;-methylene moiety. These steroids show an unexpectedly high androgenic potency.

  本发明公开了(14&bgr;,17&agr;)-17-(羟甲基)型雄激素类固醇。本发明涉及对这种类固醇的改进，改进的基础是存在一个&x3B2;取向的环丙基，环丙基包括类固醇骨架的碳原子 16 和 17，即一个 16,17&bgr;-亚甲基。这些类固醇具有意想不到的高雄激素效力。
• 14.BETA.,17-ALPHA-HYDROXYMETHYLANDROSTANE DERIVATIVES AS ANDROGENS
  申请人：Akzo Nobel N.V.

  公开号：EP1163259B1

  公开（公告）日：2002-11-20